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ABSTRACT Extracts from lymphoid and fibroblast cell
lines transformed by Abelson murine leukemia virus (A-MuLV)
contain a protein of molecular weight 120,000 (PI20). Immu-
noprecipitation with specific sera shows that P120 contains
regions homologous to the 5'-terminal segment of the MuLV gag
gene complex-p15, p12, and at least part of p30-but lacks
detectable determinants of plO, reverse transcriptase, and the
envelope glycoprotein. P120 is phosphorylated and has an in-
tracellular half-life of 3-6 hr. In vitro translation of virion RNA
from A-MuLV, with Moloney MuLV as helper, yields a product
of molecular weight 120,000 with serological reactivity similar
to that of the cellular P120. Translation of the RNA from the
helper gave no P120. P120 is expressed in all lymphoid and fi-
broblastic cell lines we have tested that were transformed by
A-MuLV but is not detectable in a lymphoid line in which the
A-MuLV genome was established by infection but was not re-
sponsible for the transformation. Expression of P120 is selec-
tively retained in clones of A-MuLV-transformed lymphocytes
that convert to a nonproducer state after loss of expression of
helper MuLV intracellular precursors. These results suggest that
the P120 product of the A-MuLV genome may be responsible
for maintenance of the transforme phenotype of lymphoid and
fibroblast cells transformed by the virus.
Abelson murine leukemia virus (A-MuLV) is a defective leu-
kemia-inducing retrovirus. It was originally isolated from a
corticosteroid-treated mouse infected with Moloney murine
leukemia virus (M-MuLV) and it generally induces a thymus-
independent lymphoma within a short period (3-6 weeks) after
in vivo inoculation (1). A-MuLV will transform a subpopulation
of bone marrow cells in vitro (2) and the resulting lines often
contain immunoglobulins (3, 4). These and other results suggest
that A-MuLV specifically transforms cells of the B lymphocyte
lineage (5-7).
A-MuLV is capable of transforming established fibroblastic
cell lines. Like the defective murine sarcoma viruses, it requires
a helper MuLV to provide essential structural components for
its replication and for production of infectious virions but
transformed cell lines lacking evidence of replication of the
helper virus can be isolated (nonproducer transformed fibro-
blasts) (8, 9).
Although any replicating MuLV appears to be able to act as
a helper for fibroblast transformation, the interaction of A-
MuLV with lymphoid target cells is more complex. Recently,
Rosenberg and Baltimore (10) and Scher (11) have demon-
strated that the successful transformation of lymphoid cells by
A-MuLV is dependent on the strain of helper MuLV used. Only
strains of MuLV that are themselves highly leukemogenic are
efficiently able to provide the helper functions necessary for
in vivo and in vitro transformation of lymphoid cells by A-
MuLV. The nature of this interaction is not understood but it
appears that the helper plays a role at least for the induction of
lymphoid cell transformation.
We have initiated a search for gene products in A-MuLV-
transformed cells that could play a role in the transformation
process. By immunoprecipitation of labeled cellular extracts
we have found a unique protein of molecular weight 120,000
(P120) that bears partial serological homology to certain of the
MuLV gene products. The presence of P120 in lymphoid and
fibroblast nonproducer cells transformed by A-MuLV, coupled
with its cell-free translation from A-MuLV virion RNA, suggests
that P120 is a product of the Abelson genome that may be in-
volved in the induction or maintenance of the transformed
state.
MATERIALS AND METHODS
Cells and Viruses. Lymphoid cell lines transformed in vitro
by A-MuLV were isolated from individual bone marrow
colonies by using the agarose transformation assay previously
described (2). SJL-46 (12), a dimethylbenzanthracene-induced
tumor in a thymectomized SJL/J mouse, was a gift of N.
Haran-Ghera, Department of Immunology, Weizmann Insti-
tute of Science, Rehovot, Israel. L-691-6 is a clone of L-691 cells
(13) that were obtained from Paul Arnstein, Viral Carcino-
genesis Branch, National Cancer Institute, National Institutes
of Health, Bethesda, MD. A-MuLV-transformed mouse fi-
broblasts were isolated by infecting NIH/3T3 cells at a low
multiplicity and cloning after the virus adsorption period.
Ab-NRK cells (9) were a gift of E. Scolnick, National Institutes
of Health, Bethesda, MD. Methods of cell growth, virus stock
preparation, and superinfection of cell lines have been described
(2, 10).
In Vitro Translation. Virion RNAs were used to program
the mRNA-dependent rabbit reticulocyte lysate system as de-
scribed (14, 15).
Immune Sera. Rabbit anti-M-MuLV reverse transcriptase,
anti-M-MuLV gp7O, and anti-M-MuLV p3O have been de-
scribed (15). Goat anti-Rauscher MuLV p15, p12, and p1O
antisera were provided through the Virus Cancer Program of
the National Cancer Institute and were prepared by R. Wils-
nack, National Cancer Institute. Goat anti-M-MuLV virions
have been described (16).
Cell Labeling and Immunoprecipitation. Subconfluent cell
monolayers of fibroblast cells or exponential phase suspension
cell lines at 2 X 106 cells per ml were labeled for the times in-
dicated in Dulbecco's minimal essential medium containing
1/50 the normal methionine concentration at 50 1tCi of [35S]-
methionine (New England Nuclear, Boston, MA) per ml. Cells
were labeled with [32P]orthophosphate (50 ,Ci/ml) (New
England Nuclear) in phosphate-free minimal essential medium
Abbreviations: A-MuLV, Abelson murine leukemia virus; M-MuLV,
Moloney murine leukemia virus; FFU, focus-forming units; PFU,
plaque-forming units; NaDodSO4, sodium dodecyl sulfate.
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for 30 min. Cells were extracted and immunoprecipitated as
detailed elsewhere (16). Briefly, cells at 1-2 X 106/ml were
lysed with 1% Triton X-100/0.5% deoxycholate/0.1% sodium
dodecyl sulfate (NaDodSO4)/0.01 M NaH2PO4, Na2HPO4/0.1
M NaCl, pH 7.5) precleared with normal serum and Staphy-
lococcus aureus Cowan strain 1 (17), and then clarified. Im-
munoprecipitates were made by incubating up to 1 ml of lysate
with 5 /Jl of immune serum and then collecting antigen-anti-
body complexes with S. aureus. 14C-Amino acid-labeled M-
MuLV virions were prepared as described (18).
NaDodSO4/Polyacrylamide Gel Electrophoresis. Immu-
noprecipitates and other samples were denatured in 1% Na-
DodSO4/1% 2-mercaptoethanol/50 mM Tris-HCl, pH 6.8/10%
glycerol and electrophoresed on 20-5% linear polyacrylamide
gradient gels as described (19, 20). Gels were fixed and fluo-
rographed as described (21).
Molecular weight estimates were interpolated from known
viral proteins of adenovirus type 2 and vesicular stomatitis virus
and standard proteins.
RESULTS
Identification of P120 in A-MuLV-Induced Lymphomas.
We have screened a number of lymphoma cell lines with a
battery of antisera prepared against leukemia virus proteins.
To show the specificities of these antisera for virion proteins,
e. kcts of purified virions of M-MuLV labeled with mixed
"4C-amino acids were immunoprecipitated at antibody excess
and the precipitates were fractionated by NaDodSO4/poly-
acrylamide gel electrophoresis (Fig. 1A). Lane 1 shows that the
anti-reverse transcriptase precipitate contained reverse tran-
scriptase (p85) and the low molecular weight component p15.
Note that the migration in NaDodSO4/polyacrylamide gel
electrophoresis of p15 is actually close to 9000-10,000 molecular
weight. This protein, however, lacks methionine. is not phos-
phorylated, and can be recovered in the appropriate processing
intermediates of the MuLV gag gene (0. N. Witte and D.
Baltimore, unpublished data), showing that it is homologous
to the NH2-terminal p15 described for Rauscher MuLV (22).
The anti-p15 activity of the anti-RT/p15 antiserum could be
adsorbed with purified MuLV low molecular weight
(10,000-30,000) proteins without affecting the precipitation
of the reverse transcriptase (p85) itself, indicating that separate
antibody molecules are responsible for the precipitation of the
two proteins (data not shown). Anti-gp7O (lane 2), anti-p3O (lane
3), anti-p15 (lane 4), anti-p12 (lane 5), and anti-plO (lane 6)
were reactive predominantly with the antigen used to induce
the antiserum. Anti-gp7O precipitated pl5E and pl2E because
they are attached to gp7O under nonreducing conditions
(20).
To reveal the proteins encoded by M-MuLV in a virus-in-
duced lymphoma, pulse-labeled ([35S]methionine) cellular
extracts from the M-MuLV-induced lymphoma B244 were
immunoprecipitated (Fig. 1B). The major viral gene products
visualized were the polyproteins Pr65sag and Pr8Oenv (23).
Some cleavage products, such as the virion structural protein
p3O, were also evident.
When a lymphoid cell line transformed in vitro by A-MuLV
plus helper M-MuLV was similarly labeled, extracted, and
immunoprecipitated a new component was found. This cell
line, called 18-48, was producing both A-MuLV and M-MuLV
when it was studied. In spite of this, the labeled extracts con-
tained little of M-MuLV-specific gag polyprotein or its cleavage
products (Fig. 1C). However, the extract had a readily detected
protein of 120,000 molecular weight (P120) that was precipi-
tated by the anti-RT/p15 (lane 1) and anti-p3O antisera (lane
3) but not by the anti-gp7O (lane 2). Pr8Oen" was precipitated
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FIG. 1. Identification of P120 in A-MuLV-induced lymphomas.
Immunoprecipitates of labeled cell and virus extracts were analyzed
on NaDodSO4/polyacrylamide gradient gels by fluorography. (A)
Specificities of antisera by immunoprecipitation of mixed 14C-amino
acid-labeled extracted virion proteins of M-MuLV. Lane 1, rabbit
anti-reverse transcriptase (RT)/pl5; lane 2, rabbit anti-gp7O; lane 3,
rabbit anti-p30; lane 4, goat anti-pl5; lane 5, goat anti-p12; and lane
6, goat anti-plO. (B) [35S]Methionine pulse-labeled (30 min) Moloney
MuLV-induced lymphoma B244. Specific sera as above. (C) [MS]-
Methionine pulse-labeled (30 min) A-MuLV (M-MuLV helper)-
induced lymphoma 18-48. Specific sera as above. (D) [34S]Methionine
pulse-labeled (30 min) and chased (60 min) 18-48 cells immunopre-
cipitated with gag gene antisera anti-p15, p12, and plO. (E) [32p]-
Orthophosphate pulse-labeled (30 min) 18-48 cells. Specific sera as
in (A).
by the anti-gp7O antiserum. The reactivity of the anti-RT/p15
antisera was removed completely by absorption with low mo-
lecular weight proteins of MuLV (data not shown). A second
anti-reverse transcriptase antiserum (from T. Papis) did not
precipitate P120 although it did precipitate reverse transcrip-
tase (p85) from virions (data not shown). Thus, P120 appears
to contain structural information related to the MuLV gag gene
products p15 and p3O but lacks detectable homology to the pol
and env gene products. A second component, of molecular
weight about 110,000, was precipitated by anti-p3O antiserum
(Fig. 1C, lane 3). It was not readily precipitated with other
anti-pSO antisera or antisera prepared against whole MuLV
virions and has not been further analyzed.
Extracts of line 18-48 cells pulse-labeled for 30 min with
[a5S]methionine and chased for 60 min in complete medium
were immunoprecipitated with gag gene-specific antisera (Fig.
1D). Anti-pi5 (lane 4) and anti-p12 (lane 5) were able to pre-
cipitate P120 but anti-plO (lane 6) was unable to do so. In longer
pulse-chase experiments, P120 was found to have an intracel-
lular half-life of 3-6 hr. No defined cleavage products have
been identified (0. N. Witte and D. Baltimore, unpublished
data). Also, line 18-48 cells pulse-labeled with 32PO4 were ex-
tracted and immunoprecipitated (Fig. 1E). P120 was seen to
be the major intracellular phosphorylated form precipitable
with anti-RT/p15 (lane 1) and anti-p30 (lane 3).
These studies show that P120 is a phosphoprotein that con-
tains homology to the 5' gene sequence of MuLV (H2N-p15-
p12-p30) but lacks serological homology to the pol or env gene
products or to plO, the COOH-terminal gag gene product.
P120 Is Found in A-MuLV Transformed Nonproducer
Lymphoid and Fibroblast Lines But May Not Be Required
for Replication of the A-MuLV Genome. A-MuLV can
transform fibroblast cell lines yielding some nonproducer lines.
The A-MuLV component can be rescued from such lines by
superinfection with another helper MuLV (8-10). We tested
such a transformed nonproducer line, NIH/3T3-derived A2,
for the presence of P120 (Fig. 2A). Extracts of cells pulse-la-
beled with [35S]methionine were immunoprecipitated with
anti-RT/plS (lane 1), anti-gp7O (lane 2), or anti-p30 (lane 3).
P120 that was precipitable by anti-RT/pl5 or anti-p3O was the
major viral polypeptide detected. This was the same serological
Microbiology: Witte et al.
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FIG. 2. P120 in additional cell lines. Immunoprecipitation
analysis (as described in Fig. 1) was of [WS]methionine pulse-labeled
(30 min) cell lines. Lanes were the same as in Fig. 1. (A) A-MuLV-
transformed NIH/3T3 nonproducer cell line A2. (B) M-MuLV-su-
perinfected A2/M cells. (C) A-MuLV-transformed lymphoid non-
producer 143-2M3 cells. (D) M-MuLV-superinfected 143-2M3/M
cells. (E) X-ray induced thymic lymphoma L-691-6 cells. (F) M-
MuLV-superinfected L-691-6/M cells. (G) A-MuLV- and M-
MuLV-superinfected L-691-6/AM cells.
specificity seen for the P120 of producer lymphoid cells
transformed by A-MuLV. A second component of 90,000-
100,000 molecular weight was also precipitated by the anti-
RT/p15 and anti-p3O antisera. A nonproducer A-MuLV-
transformed rat fibroblast line (Ab-NRK obtained from E.
Scolnick; ref. 9) contained P120 but not the lower molecular
weight component (not shown). Neither fibroblast line had any
of the normal M-MuLV precursor proteins.
A2 cells were superinfected with M-MuLV, and a producer
clone (A2/M) was derived and tested by immunoprecipitation
(Fig. 2B). P120 continued to be expressed in these cells. Proteins
corresponding to the MuLV precursors Pr65gag, Pr75gag and
Pr8Oeno were also seen (Fig. 2B, lanes 1, 2, and 3). Similarly,
when a lymphoid nonproducer cell line, 143-2M3 derived from
the in vitro transformation of bone marrow cells by A-MuLV,
was tested, it too contained P120 (Fig. 2C). Upon superinfection
of 143-2M3 with M-MuLV (Fig. 2D), P120 continued to be
expressed along with the intracellular M-MuLV precursors
Prf5gag, Pr75gag and Pr8Oenv.
These results suggest that P120 is a product of the A-MuLV
genome that is expressed in transformed nonproducer and
producing cell lines whenever A-MuLV was the transforming
agent. A large number of cell lines have been assayed for P120
to test the generality of the correlation of P120 with A-
MuLV-induced transformation (Table 1). Expression of P120
was independent of the type of cell transformed by A-MuLV
and the helper virus used in the A-MuLV stock. A-MuLV-
transformed fibroblasts of mouse and rat origin and lymphoid
cell lines from a number of mouse strains all had the protein.
P120 was present in all cases in which A-MuLV induced
transformation, regardless of which other MuLV proteins were
expressed. When a number of lymphoid cell lines transformed
by other agents were examined, none of these cells had de-
tectable P120. Included in this group were several thymic
lymphomas induced by the clone of M-MuLV helper used in
many A-MuLV stocks and the SJL/46 cell line which resembles
most A-MuLV-transformed lymphoid cells with respect to
immunologic markers (7).
To test if P120 is required for A-MuLV replication, as op-
posed to its apparent necessity for A-MuLV transformation, a
cell line transformed by a different agent was infected with
A-MuLV and a culture producing both A-MuLV and helper
M-MuLV was derived. The host cell was L-691-6, a line derived
from a thymic lymphoma caused by x-irradiation in vivo (13).
L691-6 bears the surface antigen and has the biological char-
acteristics of a thymus-derived lymphoma (7, 13). It produces
a xenotropic retrovirus but no detectable ecotropic MuLV. We
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FIG. 3. In vitro translation of P120. The mRNA-dependent re-
ticulocyte lysate system (14,15) was programmed with purified 38S
M-MuLV virion RNA subunits or heat-denatured subunits of a
mixture of A-MuLV and M-MuLV virion RNA. Samples electro-
phoresed on a NaDodSOS10% polyacrylamide gel. (A) M-MuLV
RNA total translation products labeled with [35S]methionine. (B)
A-MuLV + M-MuLV RNA total translation product. (C) Immu-
noprecipitation of an aliquot of A-MuLV + M-MuLV product with
anti-RT/p15 serum. (D) Intracellular standards (P120, PrO5gag, and
Pr8Oenv) prepared from 143-2M3/M cells.
superinfected L691-6 with M-MuLV (L691-6/M) or A-MuLV
stocks containing M-MuLV as a helper (L691-6/AM). Labeled
cell extracts from L691-6 (Fig. 2E), L691-6/M (Fig. 2F), and
L691-6/AM (Fig. 2G) were immunoprecipitated with specific
sera. None of the cell lines contained P120. This included
L691-6/AM which was found to replicate and produce infec-
tious, oncogenic A-MuLV particles (Table 1). L691-6/M and
L691-6/AM both contained intracellular precursors of M-
MuLV (Pr65gag and Pr8Oenv). Although these results do not
eliminate the possibility that very small amounts of P120 may
be produced and provide an essential function for A-MuLV
replication, reconstruction experiments indicate that L691-
6/AM cells express less than 5% of the level of P120 found in
lymphoid cell lines (such as line 18-48) transformed by A-
MuLV. We therefore conclude that P120 is probably not re-
quired for productive A-MuLV infection.
In Vitro Translation of P120 from A-MuLV Virion RNA.
To determine if the A-MuLV genome can direct synthesis of
P120 in a cell-free system, 60-70S RNA was purified from a
mixture of A-MuLV and M-MuLV harvested from a trans-
formed fibroblast cell line, and the RNA was heat denatured
to yield 30-38S subunits. As a control, pure 38S MuLV RNA (a
kind gift of P. Andersson) was translated. Fractions precipitated
from ethanol were used for translation in the mRNA-dependent
reticulocyte lysate system (14, 15). Fig. 3A shows the pattern
of total synthesis for the M-MuLV RNA preparation. No P120
was evident and the previously described viral components
corresponding to Pr65gag and Pr75gag were the major trans-
lation products (15). When A-MuLV virion RNA was translated
(Fig. 3B), an additional band of molecular weight 120,000 was
detected which comigrated with P120 immunoprecipitated
from cellular lysate. Immunoprecipitation with anti-RT/p15
(Fig. 3C) showed that the cell-free product had the same
serological reactivity as the intracellular P120. P120, Pr8Oenv,
and Pr65gag immunoprecipitated from cellular lysates (Fig.
3D) are shown as markers. These results show that the A-MuLV
2490 Microbiology: Witte et al.
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Table 1. Biological phenotypes and intracellular viral proteins of transformed cell lines
Virus Reverse
Cell Mouse productionr transcriptase, Proteins
Origin Helper line strain Ref. PFU/ml FFU/ml cpm X 10-3 Pr65gag Pr8Oenv P120
By A-MuLV
In vitro
transformed
bone marrow
(lymphoid)
M-MuLV 18-48
18-8
SWR-4
SWR-4/M
BR 48-1
BR 48-1/M
143-2M3
143-2M3/M
TB-7
TB-6
L1-2
Friend 143-3B
M-MuLV A2
A2/M
Ab-NRK
M- MuLV AB4-2
BALB/cJ
BALB/cJ
SWR/J
SWR/J
C57BR/cdJ
C57BR/cdJ
BALB/cAN
BALB/cAN
NIH/Swiss
NIH/Swiss
C57L/J
BALB/cAN
NIH/Swiss
NIH/Swiss
(NIH/3T3)t
(NIH/3T3)t
(NRK)t
BALB/cJ
7 7X104
7 0
7 0
5 X 104
10 0
10 5 X 105
10 0
10 3 X 105
5 X 102
0
7 0
10 0
8 X 103
0
0
8 X 104
0
5 X 104
0
1 X 105
3 X 102
0
0
0
0 0
NT NT
0
3 X 105
9 0
0
1 X 105
0
26.6
12.0
19.0
46.2
0.29
55.5
0.26
NT
1.0
0.30
0.30
7.1
+ + +
+ + +
-
+
+ + +
_ + +
+ + +
-
+
+ + +
+ + +
+ +
+ + +
_ + +
_ + +
NT + + +
NT
42.5
NT
-
+
+ + +
-
+
NT NT NT + + +
L-691-6
L-691-6/M
L-691-6/AM
C57L/J
C57L/J
C57L/J
By x-ray
10,13
10
By carcinogen
0
7 X 105
7 X 105
0
NT
2 X 104
0.2
NT
28.5
+ + -
+ +
-
SJL/46
MT-4
MT-11
B244
SJL/J 12 <50 0 13.4
By M-MuLV
HaM/ICR CD-1
HaM/ICR CD-1
BALB/cJ
* Virus production was monitored by using infectivity and reverse transcriptase assays according to standard procedures (2, 10). PFU were
measured by using the S+L- assay (24); FFU were monitored by using the NIH/3T3 or BALB/3T3 focus assay (8). Reverse transcriptase
values represent cpm/106 cells. NT, not tested.
t Cell line used for transformation noted, not animal strain.
genome codes for the P120 protein.
Retention of P120 in Cloned Cell Lines That Convert to
Nonproducer Status. During the course of these studies the
cloned A-MuLV-transformed producer cell line, 18-48, was
serially followed for production of M-MuLV [S+L- assay, PFU
(24)] and A-MuLV [focus assay, FFU (8)]. Over a 4-month
period, both the PFU and FFU titers decreased to almost 1/10
as did the reverse transcriptase activity of released virions.
When line 18-48 cells were subcloned and the clones were
tested individually for biological activity, only one in five
produced high titers of infectious virus. The intracellular pro-
teins expressed in the four nonproducer subclones (18-48-1, -2,
-3, and -5) (<10 FFU/ml) and one producer subclone (18-48-4)
(>104 FFU/ml) were assayed. Pulse-labeled cellular extracts
were immunoprecipitated with an antiserum prepared against
disrupted M-MuLV virions that had specificity for gag and env
gene products (Fig. 4). All of the subclones retained the ex-
pression of P120 and Pr8Oenv. Only the producer subclone re-
tained expression of Pr65gag and Prl180ag-Pol gene prod-
ucts.
DISCUSSION
Of the 16 lymphoid and fibroblastic cell lines transformed by
A-MuLV that we have assayed, all contained P120. The oc-
currence of P120 in nonproducer cells as well as its translation
from A-MuLV RNA strongly implies that it is a product of the
A-MuLV genome. Although genetic data are required to prove
that P120 is involved in A-MuLV-induced cell transformation,
it seems likely that P120 has such a role.
P120 is apparently not needed, at least in large amounts, for
A-MuLV replication because a producer cell originally trans-
formed by x-rays, L691-6/AM, had no detectable P120. This
result is consistent with the provision of all A-MuLV proteins
by its helper virus.
The A-MuLV genome has yet to be physically characterized
but the recent demonstration of a 28-S RNA correlating with
A-MuLV biological activity suggests that this may be the ge-
nome (A. Shields, unpublished data). If so, the genome would
be about 5000 bases and could encode a protein as large as
200,000 molecular weight. Thus, P120 might not be the only
MuLV
Gross
MuLV
Rauscher
MuLV
131-1
185-1
In vitro
transformed
fibroblast
In vivo
lymphoid
tumor
In vivo
thymoma
In vivo
lymphoma
In vivo
thymoma
6 X 104
0
NT
NT
0
NT
NT
1.1
NT
+ +
+ +
+ +
+ +
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FIG. 4. Maintenance of P120 in the conversion to nonproducer
status. [35S]Methionine pulse-labeled (30 min) subclones (1-5) of the
A-MuLV-transformed (M-MuLV as helper) producer clone 18-48
were tested for intracellular precursors by immunoprecipitation with
a polyvalent goat anti-MuLV virions antiserum. Precipitates were
electrophoresed on a NaDodSO410% polyacrylamide gel.
A-MuLV-specified product. Retroviruses may have 1000-1500
more bases than are needed to encode their known proteins (25),
so it is conceivable that P120 is the only A-MuLV-specified
protein. If a protein lacking any M-MuLV-specific antigenicity
were synthesized by A-MuLV, we could not have detected it
in these studies. In certain cell lines, proteins of molecular
weight 100,000-110,000 were seen along with P120 (Fig. 2 A
and B); their sporadic occurrence suggests that they may be
degradation products of P120 but they may deserve further
attention.
Our serological data imply that the A-MuLV genome en-
codes some but not all of the gag proteins of its parent, M-
MuLV. The 5'-terminal portions of the gag polyprotein
(Pr65gaS), p15 and p12, are represented in P120, and our M-
MuLV-specific anti-p,30 recognizes P120 also. Previous studies
found p15 and p12 but not p30 determinants among the A-
MuLV-specified products (9) and we have also found an anti-
p30 antiserum that will not recognize P120. We therefore be-
lieve that P120 results from a fusion of the 5' end of the M-
MuLV genome somewhere within the p30 coding region to a
genetic region of undetermined origin. Although 30,000-5,000
daltons of P120 are M-MuLV in origin, the rest has no antige-
nicity that we can yet define. No anti-RT or anti-gp7O antise-
rum can recognize P120 (except in the case of the strong anti-
p15 reactivity of our anti-RT antiserum) and we therefore be-
lieve that the A-MuLV genome probably has a genetic region
not found in M-MuLV.
Comparison of P120 to the gene products of several other
defective leukemia/sarcoma viruses in the retrovirus group
shows interesting parallels. Murine sarcoma virus P60 (26),
avian virus MC29 P110 (27), and feline sarcoma virusFOCMA
antigen (90,000-100,000 molecular weight) (28) all contain
some structural homology to the 5' end of the gag gene of the
original helper virus from which they were isolated. Thus,
oncogenic retroviruses may often arise from fusion of the 5'-
terminal portion of the gag region with other genetic materi-
al.
Although P120 is quite possibly responsible for fibroblast
transformation by A-MuLV, the evidence for a helper function
in A-MuLV lymphoid cell transformation implies that P120 is
not sufficient to explain lymphoid transformation. Because no
M-MuLV protein was evident in nonproducer lymphoid
transformants, a role for the helper in maintenance of the
transformed state is not indicated and it may be needed only
for establishing transformation.
In cells producing A-MuLV and helper MuLV, the P120 is
very stable intracellularly during pulse-chase experiments with
a half-life of 3-6 hr. Only a small fraction can be recovered in
the supernatant medium and only a fraction of this is found in
the particulate fraction containing virus (unpublished data).
No defined cleavage products of P120 are seen to accumulate
intracellularly but only those retaining MuLV antigenicity
could be recovered in these experiments. Preliminary cell
fractionation studies have recovered a large fraction (80-90%)
of P120 in membrane-bound form but we are as yet uncertain
how much, if any, is found on the cell surface.
This work was supported by a grant from the American Cancer
Society, Grant CA-14051 from the National Cancer Institute, and a
contract from the Virus Cancer Program of the National Cancer In-
stitute. O.N.W. is a postdoctoral fellow of the Helen Hay Whitney
Foundation. D.B. is a Research Professor of the American Cancer So-
ciety.
1. Abelson, H. T. & Rabstein, L. S. (1970) Cancer Res. 30,2213-
2222.
2. Rosenberg, N. & Baltimore, D. (1976) J. Exp. Med. 143,
1453-1463.
3. Pratt, D. M., Strominger, J., Parkman, R., Kaplan, D., Schwaber,
J., Rosenberg, N. & Scher, C. D. (1977) Cell 12,683-690.
4. Prekumar, E., Potter, M., Singer, P. A. & Sklar, M. D. (1975) Cell
6, 149-159.
5. Potter, M., Sklar, M. D. & Rowe, W. P. (1973) Science 182,
592-594.
6. Sklar, M. D., Shevach, E. M., Green, I. & Potter, M. (1975) Nature
253,550-552.
7. Silverstone, A. E., Rosenberg, N., Sato, V. L., Scheid, M. P., Boyse,
E. A. & Baltimore, D. (1978) Control of Cell Proliferation (Cold
Spring Harbor Press, Cold Spring Harbor, NY), Vol. 5, in
press.
8. Scher, C. D. & Siegler, R. (1975) Nature 253, 729-731.
9. Parks, W. P., Hawk, R. S., Anisowicz, A. & Scolnick, E. M. (1976)
J. Virol. 18,491-503.
10. Rosenberg, N. & Baltimore, D. (1978) J. Exp. Med. 147,
1126-1141.
11. Scher, C. D. (1978) J. Exp. Med. 147, 1044-1053.
12. Haimovich, J., Bergman, Y., Linker-Israeli, M. & Haran-Ghera,
N. (1977) Eur. J. Immunol. 7,226-230.
13. Arnstein, P., Riggs, J. L., Oshiro, L. S., Huebner, R. J. & Lennette,
E. H. (1976) J. Natl. Cancer Inst. 57, 1085-1090.
14. Pelham, H. R. B. & Jackson, R. J. (1976) Eur. J. Biochem. 67,
247-256.
15. Philipson, L., Andersson, P., Olshevsky, U., Weinberg, R., Bal-
timore, D. & Gesteland, R. (1978) Cell 13, 189-199.
16. Witte, 0. N. & Baltimore, D. (1978) J. Virol., in press.
17. Kessler, S. W. (1975) J. Immunol. 115, 1617-1624
18. Witte, 0. N. & Weissman, I. L. (1974) Virology 61,575-587.
19. Laemmli, U. K. (1970) Nature 227,680-685.
20. Witte, 0. N., Tsukamoto-Adey, A. & Weissman, I. L. (1977)
Virology 76,539-553.
21. Bonnar, W. M. & Laskey, R. A. (1974) Eur. J. Blochem. 46,
83-88.
22. Barbacid, M., Stephenson, J. R. & Aaronson, S. A. (1976) Nature
262,554-559.
23. Jamjoom, G. A., Naso, R. B. & Arlinghaus, R. (1977) Virology 78,
11-34.
24. Bassin, R. H., Tuttle, N. & Fischinger, P. J. (1971) Nature 269,
564-566.
25. Rothenberg, E., Donoghue, D. J. & Baltimore, D. (1978) Cell 13,
435-451.
26. Robey, W. G., Oskarrsson, M. K., Van de Woude, G. F., Naso,
R. B., Arlinghaus, R. B., Haapala, D. & Fischinger, P. J. (1977)
Cell 10, 79-89.
27. Bister, K., Hayman, M. J. & Vogt, P. K. (1977) VIrology 82,
431-448.
28. Stephenson, J. R., Khan, A. S., Sliski, A. H. & Essex, M. (1977)
Proc. Natl. Acad. Sci. USA 74,5608-5612.
2492 Microbiology: Witte et al.
